title: [Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab].
abstract: Nowadays, the advancements of systemic chemotherapy for colorectal carcinoma improve a clinical response rate, and expand the possibility of resection which couldn't operable at the initial visit. In addition, the prognoses of the patients, who had a radical operation for metastasis, are clearly longer than the non-operable patients. Bevacizumab, anti-human VEGF monoclonal antibody, is significantly effective when used in combination with one of the systemic multi-agent chemotherapy such as FOLFOX regimen or FOLFIRI regimen. We report here two cases with colon carcinoma, which had initially unresectable liver metastases, were respond to the treatment of systemic multi-agent chemotherapy with bevacizumab. Then, both cases were able to undergo radical resections of primary tumor and liver metastases safely.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sugiyama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kakeji
authors.forename: Nobuhide
authors.initials: N
authors.lastname: Kubo
authors.forename: Tomonori
authors.initials: T
authors.lastname: Nakanoko
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Fujinaka
authors.forename: Kouji
authors.initials: K
authors.lastname: Ando
authors.forename: Takanobu
authors.initials: T
authors.lastname: Masuda
authors.forename: Kenji
authors.initials: K
authors.lastname: Yagi
authors.forename: Keishi
authors.initials: K
authors.lastname: Yoshinaga
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saeki
authors.forename: Kazuya
authors.initials: K
authors.lastname: Endo
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Emi
authors.forename: Masaru
authors.initials: M
authors.lastname: Morita
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maehara
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab